We use cookies to understand how you use our site and to improve your experience.
This includes personalizing content and advertising.
By pressing "Accept All" or closing out of this banner, you consent to the use of all cookies and similar technologies and the sharing of information they collect with third parties.
You can reject marketing cookies by pressing "Deny Optional," but we still use essential, performance, and functional cookies.
In addition, whether you "Accept All," Deny Optional," click the X or otherwise continue to use the site, you accept our Privacy Policy and Terms of Service, revised from time to time.
You are being directed to ZacksTrade, a division of LBMZ Securities and licensed broker-dealer. ZacksTrade and Zacks.com are separate companies. The web link between the two companies is not a solicitation or offer to invest in a particular security or type of security. ZacksTrade does not endorse or adopt any particular investment strategy, any analyst opinion/rating/report or any approach to evaluating individual securities.
If you wish to go to ZacksTrade, click OK. If you do not, click Cancel.
Stay Ahead of the Game With Labcorp (LH) Q4 Earnings: Wall Street's Insights on Key Metrics
Read MoreHide Full Article
Analysts on Wall Street project that Labcorp Holdings (LH - Free Report) will announce quarterly earnings of $3.95 per share in its forthcoming report, representing an increase of 14.5% year over year. Revenues are projected to reach $3.55 billion, increasing 6.6% from the same quarter last year.
Over the last 30 days, there has been an upward revision of 0.2% in the consensus EPS estimate for the quarter, leading to its current level. This signifies the covering analysts' collective reconsideration of their initial forecasts over the course of this timeframe.
Before a company announces its earnings, it is essential to take into account any changes made to earnings estimates. This is a valuable factor in predicting the potential reactions of investors toward the stock. Empirical research has consistently shown a strong correlation between trends in earnings estimate revisions and the short-term price performance of a stock.
While it's common for investors to rely on consensus earnings and revenue estimates for assessing how the business may have performed during the quarter, exploring analysts' forecasts for key metrics can yield valuable insights.
In light of this perspective, let's dive into the average estimates of certain Labcorp metrics that are commonly tracked and forecasted by Wall Street analysts.
Analysts forecast 'Revenues- Diagnostics Laboratories' to reach $2.77 billion. The estimate points to a change of +7% from the year-ago quarter.
Analysts predict that the 'Revenues- Biopharma Laboratory Services' will reach $791.05 million. The estimate indicates a change of +3.1% from the prior-year quarter.
The consensus among analysts is that 'Adjusted Operating Income- Diagnostics Laboratories' will reach $423.58 million. The estimate is in contrast to the year-ago figure of $359.50 million.
Analysts' assessment points toward 'Adjusted Operating Income- Biopharma Laboratory Services' reaching $130.10 million. The estimate is in contrast to the year-ago figure of $130.80 million.
Shares of Labcorp have demonstrated returns of +12% over the past month compared to the Zacks S&P 500 composite's -0.3% change. With a Zacks Rank #3 (Hold), LH is expected to mirror the overall market performance in the near future. You can see the complete list of today's Zacks Rank #1 (Strong Buy) stocks here >>>> .
View the Zacks #1 Rank List
Image: Bigstock
Stay Ahead of the Game With Labcorp (LH) Q4 Earnings: Wall Street's Insights on Key Metrics
Analysts on Wall Street project that Labcorp Holdings (LH - Free Report) will announce quarterly earnings of $3.95 per share in its forthcoming report, representing an increase of 14.5% year over year. Revenues are projected to reach $3.55 billion, increasing 6.6% from the same quarter last year.
Over the last 30 days, there has been an upward revision of 0.2% in the consensus EPS estimate for the quarter, leading to its current level. This signifies the covering analysts' collective reconsideration of their initial forecasts over the course of this timeframe.
Before a company announces its earnings, it is essential to take into account any changes made to earnings estimates. This is a valuable factor in predicting the potential reactions of investors toward the stock. Empirical research has consistently shown a strong correlation between trends in earnings estimate revisions and the short-term price performance of a stock.
While it's common for investors to rely on consensus earnings and revenue estimates for assessing how the business may have performed during the quarter, exploring analysts' forecasts for key metrics can yield valuable insights.
In light of this perspective, let's dive into the average estimates of certain Labcorp metrics that are commonly tracked and forecasted by Wall Street analysts.
Analysts forecast 'Revenues- Diagnostics Laboratories' to reach $2.77 billion. The estimate points to a change of +7% from the year-ago quarter.
Analysts predict that the 'Revenues- Biopharma Laboratory Services' will reach $791.05 million. The estimate indicates a change of +3.1% from the prior-year quarter.
The consensus among analysts is that 'Adjusted Operating Income- Diagnostics Laboratories' will reach $423.58 million. The estimate is in contrast to the year-ago figure of $359.50 million.
Analysts' assessment points toward 'Adjusted Operating Income- Biopharma Laboratory Services' reaching $130.10 million. The estimate is in contrast to the year-ago figure of $130.80 million.
View all Key Company Metrics for Labcorp here>>>Shares of Labcorp have demonstrated returns of +12% over the past month compared to the Zacks S&P 500 composite's -0.3% change. With a Zacks Rank #3 (Hold), LH is expected to mirror the overall market performance in the near future. You can see the complete list of today's Zacks Rank #1 (Strong Buy) stocks here >>>> .